Hybrid Sr. Director / Executive Director, Patient Services at Cogentbiosciences
Cogentbiosciences · Waltham, Massachusetts, United States Of America · Hybrid
- Office in Waltham, Massachusetts
Who We Are
Cogent Biosciences is a publicly traded biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Top-line results from registration-directed trials in NonAdvanced SM, Advanced SM and GIST are expected in 2025. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS.
Our Team
This role will have responsibility for the design, build and scaling of the Cogent Biosciences Patient Support operations for Cogent’s oncology and rare disease portfolio. In this patient centric role, you will be responsible for delivering innovative, patient-focused support options for each therapeutic area and establishing a strong relationship with the brand and external hub partners. This role will report into the Senior Vice President, Market Access.
